This activity highlights key updates in the 2026 ADA Standards of Care, focusing on changes that impact pharmacist-led medication selection, monitoring, and patient counseling. Updates to glucose-lowering therapies, diabetes technology, and cardiovascular, kidney, and obesity management will be reviewed to support evidence-based diabetes care.

Course Details

Date: Thursday, February 12, 2026
Time: 10 a.m. to 11 a.m. via webinar
(Webinar will also be available on demand following the event if your schedule does not allow for live viewing.)

Presented by:
Christine Lam, PharmD, BCPS, BCACP, CDCES, BCGP • Assistant Professor, Pharmacy Practice, University of the Incarnate Word Feik School of Pharmacy

CE Credit:
This lesson is a knowledge-based CE activity and is targeted to pharmacists and technicians. This program has been approved for 1.0 contact hours of continuing education credit (0.1 CEU).

• Pharmacists: 0154-0000-26-002-L01-P
• Technicians: 0154-0000-26-002-L01-T

Pricing:
Members: FREE (Log in to your TPA account to receive free CE.)
Non-Members: $25

Learning Objectives:

At the completion of this activity, the pharmacist will be able to:

1. Identify key changes in the 2026 American Diabetes Association Standards of Care that impact medcation selection, monitoring, and patient counseling.
2. Describe updates to glucose-lowering therapies and diabetes technology, including expanded use of continuous glucose monitoring (CGM), automated insulin delivery, and newer pharmacologic agents.
3. Apply updated recommendations for cardiovascular, kidney, and obesity management to optimize medication therapy management and collaborative care. 

At the completion of this activity, the pharmacy technician will be able to:

1. Identify key changes in the 2026 American Diabetes Association Standards of Care that impact medcation selection, monitoring, and patient counseling.
2. Describe updates to glucose-lowering therapies and diabetes technology, including expanded use of continuous glucose monitoring (CGM), automated insulin delivery, and newer pharmacologic agents.